How large is the seasonal influenza market, and what is its growth trajectory?
The seasonal influenza market size has grown rapidly in recent years. It will grow from $8.41 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to the rising prevalence of influenza, growth in the elderly population, rise in the prevalence of infectious and chronic diseases, growing burden of influenza-related illness, and rise in respiratory infections.
The seasonal influenza market size is expected to see rapid growth in the next few years. It will grow to $18.55 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to increasing demand for oral drug solutions, expanding research and development activities, increasing vaccination counts, improving healthcare infrastructure, and increasing demand for retail pharmacies. Major trends in the forecast period include advancement in the treatment, advancement in technology, advancements in vaccine technology, mRNA technology, and digital health solutions for monitoring and diagnosis.
Get Your Free Sample of The Global Seasonal Influenza Market Report:
Seasonal Influenza Market Overview And Growth Report 2025-2034 Sample
What are the key forces behind the seasonal influenza market’s growth in recent years?
The increasing prevalence of respiratory infections is expected to propel the growth of the seasonal influenza market going forward. Respiratory infections are illnesses caused by viruses or bacteria affecting the respiratory system, including the sinuses, throat, airways, or lungs. The increasing prevalence of respiratory infections is driven by air pollution, changing climates, weakened immune responses, and the ease of viral transmission in crowded or poorly ventilated spaces. Seasonal influenza treatment helps prevent or reduce the severity of respiratory infections in several ways, primarily by addressing the influenza virus and managing symptoms that can lead to secondary infections. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, the number of tuberculosis (TB) (a respiratory infection caused by the bacterium Mycobacterium tuberculosis) cases in England experienced a 10.7% year-over-year increase in 2023, rising from 4,380 cases in 2022 to 4,850 cases. Therefore, the rise in respiratory infections will drive the growth of the seasonal influenza market.
What are the major segments of the seasonal influenza market?
The seasonal influenza market covered in this report is segmented –
1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online
4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments
Subsegments:
1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes
2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata
3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus
4) By Influenza D Virus: Animal-associated Influenza D
Order your report now for swift delivery
Seasonal Influenza Market Overview And Growth Report 2025-2034
Which companies dominate the seasonal influenza market?
Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.
What major trends will shape the seasonal influenza market during the forecast period?
Major companies operating in the seasonal influenza market are focusing on advancements in treatment, such as combination vaccines, to enhance immunity by targeting multiple strains of the virus, improving effectiveness, and reducing the need for frequent vaccinations. Combination vaccines protect against multiple diseases or strains with a single injection, reducing the number of shots needed for immunization. For instance, in October 2023, Moderna, Inc., a US-based biotechnology company, announced positive interim Phase 1/2 trial results for mRNA-1083, its investigational combination vaccine targeting both influenza and COVID-19. Designed to enhance compliance, streamline administration, and improve convenience for individuals and healthcare systems, mRNA-1083 is being evaluated for safety and immunogenicity against standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), as well as compared to the Spikevax booster.
What are the key regional dynamics of the seasonal influenza market, and which region leads in market share?
North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Seasonal Influenza Market Report 2025 Offer?
The seasonal influenza market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Seasonal influenza, commonly known as the flu, is a contagious respiratory infection caused by influenza viruses that circulate globally, primarily during specific seasons (typically fall and winter in temperate regions). It spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Seasonal influenza leads to widespread illness and can result in serious complications, particularly for vulnerable populations such as the elderly and those with weakened immune systems.
Purchase the exclusive report now to unlock valuable market insights:
Seasonal Influenza Market Overview And Growth Report 2025-2034
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Twitter: The Business Research Company (@tbrc_info) on X
Facebook: The Business Research Company | London
YouTube: The Business Research Company
Blog: In-Depth Insights into the Implantable Loop Recorders Market: Growth, Trends, and Opportunities for 2025-2034 – Latest Global Market Insights
Healthcare Blog: Latest Healthcare Research Reports – By The Business Research Company
Global Market Model: Global Market Intelligence Database
